But the $1B in revenue won’t belong to PYC unless it funds the Phase 2/3 itself, and it doesn’t have the funds to do that IMO.
Therefore, the most likely way forward is to license the drug out to (at least some) countries.
At least that funding is non-dilutive.
But the $1B in revenue won’t belong to PYC unless it funds the...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.13 |
Change
-0.020(1.74%) |
Mkt cap ! $659.0M | |||
| Open | High | Low | Value | Volume |
| $1.17 | $1.19 | $1.13 | $187.3K | 162.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 5698 | $1.13 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.15 | 938 | 1 |
View Market Depth
| Last trade - 16.10pm 19/06/2025 (20 minute delay) ? |
| PYC (ASX) Chart |